Article
Oncology
Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, Riccardo Ponzone, Antonio Durando, Laura Amaducci, Enrico Campadelli, Francesco Cognetti, Antonio Frassoldati, Andrea Michelotti, Silvia Mura, Ylenia Urracci, Giovanni Sanna, Stefania Gori, Sabino De Placido, Ornella Garrone, Alessandra Fabi, Carla Barone, Stefano Tamberi, Claudia Bighin, Fabio Puglisi, Gabriella Moretti, Grazia Arpino, Alberto Ballestrero, Francesca Poggio, Matteo Lambertini, Filippo Montemurro, Paolo Bruzzi
Summary: The study showed that extending letrozole treatment to 5 years in postmenopausal patients with breast cancer who had received 2-3 years of tamoxifen resulted in a significant improvement in disease-free survival compared to the standard 2-3 years of letrozole treatment.
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Michael Gnant, Florian Fitzal, Gabriel Rinnerthaler, Guenther G. Steger, Sigrun Greil-Ressler, Marija Balic, Dietmar Heck, Raimund Jakesz, Josef Thaler, Daniel Egle, Diether Manfreda, Vesna Bjelic-Radisic, Ursula Wieder, Christian F. Singer, Elisabeth Melbinger-Zeinitzer, Ferdinand Haslbauer, Paul Sevelda, Harald Trapl, Viktor Wette, Kerstin Wimmer, Simon P. Gampenrieder, Rupert Bartsch, Stephanie Kacerovsky-Strobl, Christoph Suppan, Christine Brunner, Christine Deutschmann, Lidija Soelkner, Christian Fesl, Richard Greil
Summary: This study showed that extending hormone therapy by 5 years in postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Oncology
Steven Davies, Ioannis A. Voutsadakis
Summary: This study found that adjuvant chemotherapy is associated with better adherence to hormonal therapy in early ER-positive breast cancer patients, while patients with psychiatric co-morbidities are more likely to be non-adherent to hormonal therapy.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Article
Oncology
Erwei Zeng, Wei He, Karin E. Smedby, Kamila Czene
Summary: Hormone therapy-related hot flashes may indicate worse breast cancer outcomes and higher treatment discontinuation rates among patients, particularly those with low income or without relatives who have had cancer or died from cancer.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Oncology
Edoardo Isnaldi, Francois Richard, Maxim De Schepper, Sophia Leduc, Marion Maetens, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Ghizlane Rouas, Gabriele Zoppoli, Fatima Cardoso, Christos Sotiriou, Denis Larsimont, Giuseppe Floris, Elia Biganzoli, Christine Desmedt
Summary: The impact of adiposity on the efficacy of endocrine treatment in patients with estrogen receptor positive breast cancer was investigated retrospectively. It was found that obesity and larger adipocyte diameter are associated with a higher likelihood of anti-proliferative response in neoadjuvant treatment.
Article
Endocrinology & Metabolism
Bjorn-Erik Bertelsen, Kristin Viste, Thomas Helland, Magnus Hagland, Havard Soiland, Jurgen Geisler, Tone Hoel Lende, Per Eystein Lonning, Jorn Sagen, Gunnar Mellgren, Bjorg Almas
Summary: This study developed a liquid chromatography-tandem mass spectrometry (MS/MS) method for simultaneous measurement of serum levels of third-generation aromatase inhibitors (AIs) and ultra-low levels of estrogens. The method is highly valuable for studying drug efficacy and compliance.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Chanhyun Park, Ji-Haeng Heo, Sanica Mehta, Sola Han, Jennifer C. Spencer
Summary: This study aimed to estimate the impact of individual adjuvant endocrine therapy (AET) types on treatment efficacy and overall survival in breast cancer patients. The study found that the tamoxifen group had a faster decrease in adherence compared to anastrozole, letrozole, and exemestane, and higher adherence was associated with a lower risk of mortality.
CLINICAL DRUG INVESTIGATION
(2023)
Article
Multidisciplinary Sciences
Kaiyue Wang, Lu Shen, Wei Tian, Suzhan Zhang
Summary: This retrospective cohort study aimed to investigate the effect of endocrine therapy on serum lipids in premenopausal women with early breast cancer. The results showed that different types of endocrine treatments had varying effects on blood lipids, with some treatments improving lipid levels but also carrying certain risks.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Cristina Ferreira Almeida, Natercia Teixeira, Maria Joao Valente, Anne Marie Vinggaard, Georgina Correia-da-Silva, Cristina Amaral
Summary: Estrogen receptor-positive (ER+) breast cancer accounts for 70-85% of cases and combining CBD with aromatase inhibitors (AIs) may improve treatment effectiveness. CBD potentiates the anti-tumor effects of exemestane (Exe) by modulating cell death and specific targets such as ERa and AR. This study highlights the potential benefits of combining CBD with Exe and suggests new therapeutic approaches using cannabinoids.
Article
Medicine, General & Internal
Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice Andre, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O'Shaughnessy
Summary: First-line therapy with ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole in patients with HR-positive, HER2-negative advanced breast cancer. Median overall survival was more than 12 months longer with ribociclib than with placebo.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Raffaella D'Onofrio, Isabella Sperduti, Federico Piacentini, Monica Barbolini, Claudia Omarini, Angela Toss, Laura Cortesi, Elena Barbieri, Fabio Canino, Massimo Dominici, Luca Moscetti
Summary: Aromatase inhibitors (AIs) as an upfront strategy are associated with the lowest TE incidence. The switch strategy increases the risk of TE events, while the addition of CDK4/6 inhibitors significantly increases TE incidence.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Abhijit Mazumdar, William M. Tahaney, Jamal L. Hill, Yun Zhang, Sumankalai Ramachandran, Jitesh Kawedia, Jing Qian, Alejandro Contreras, Michelle I. Savage, Lana A. Vornik, Shizuko Sei, Altaf Mohammed, Powel H. Brown
Summary: This study demonstrates that the mTOR inhibitor everolimus can effectively delay the formation of ER-negative mammary tumors and suppress the proliferation of normal mammary gland cells. These results provide support for the use of everolimus in clinical trials for the prevention of ER-negative breast cancer.
CANCER PREVENTION RESEARCH
(2022)
Article
Oncology
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Bjorn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Summary: This study compared different dosing schedules of exemestane, an aromatase inhibitor, in patients with breast cancer. The results showed that a 25mg dose taken three times weekly was as effective as a daily dose in decreasing serum estradiol levels, suggesting that this alternative schedule warrants further investigation.
Article
Oncology
J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I Molnar, S. Levesque, R. Bellini, F. Kwiatkowski, L. Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando
Summary: This phase 1 trial aimed to determine the maximum tolerated dose of a p38-MAPK inhibitor, ralimetinib, in combination with radiotherapy and chemotherapy for newly diagnosed GBM patients. The study found that the MTD of ralimetinib was 100 mg/12 h, with the main dose-limiting toxicities being hepatic cytolysis and rash.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Maureen Bernadach, Michel Lapeyre, Anne-Francoise Dillies, Jessica Miroir, Melanie Casile, Juliette Moreau, Ioana Molnar, Angeline Ginzac, Nathalie Pham-Dang, Nicolas Saroul, Xavier Durando, Julian Biau
Summary: The study investigated predictive factors of toxicity of induction chemotherapy with TPF in locally advanced head and neck cancers, finding that nutritional status and hepatic dysfunction are significant risk factors to consider in therapeutic decisions.
Article
Oncology
C. Cabanie, J. Biau, X. Durando, S. Mansard, I Molnar, V Chassin, P. Verrelle, T. Khalil, M. Lapeyre, G. Dupic
Summary: The study found that the time lapse between immunotherapy and stereotactic radiotherapy does not affect brain toxicity, with tumor volume being the main predictive factor.
CANCER RADIOTHERAPIE
(2021)
Article
Oncology
Hesham Elghazaly, Hope S. Rugo, Hamdy A. Azim, Sandra M. Swain, Banu Arun, Matti Aapro, Edith A. Perez, Benjamin O. Anderson, Frederique Penault-Llorca, Pierfranco Conte, Nagi S. El Saghir, Cheng-Har Yip, Marwan Ghosn, Philip Poortmans, Mohamed A. Shehata, Armando E. Giuliano, Jessica W. T. Leung, Valentina Guarneri, Joseph Gligorov, Bahadir M. Gulluoglu, Hany Abdel Aziz, Mona Frolova, Mohamed Sabry, Charles M. Balch, Roberto Orecchia, Heba M. El-Zawahry, Sana Al-Sukhun, Khaled Abdel Karim, Alaa Kandil, Ruslan M. Paltuev, Meteb Foheidi, Mohamed El-Shinawi, Manal ElMahdy, Omalkhair Abulkhair, Wentao Yang, Adel T. Aref, Joaira Bakkach, Nermean Bahie Eldin, Hagar Elghazawy
Summary: During the TNBC consensus recommendations session at the 12th BGICC in Egypt 2020, a panel of 35 breast cancer experts from 13 countries reached a consensus on clinical management of TNBC, covering all aspects from defining TNBC to managing metastatic disease and highlighting the rapidly evolving landscape in the field.
Article
Oncology
Angeline Ginzac, Guillaume Dupic, Lucie Brun, Ioana Molnar, Melanie Casile, Xavier Durando, Pierre Verrelle, Jean-Jacques Lemaire, Toufic Khalil, Julian Biau
Summary: BackgroundSurgery is a crucial treatment for brain metastases, but postoperative stereotactic radiosurgery (SRT) comes with risks. Preoperative SRT is proposed as an alternative to reduce risks, and the STEP trial is the first prospective study in Europe to assess its effectiveness.
Article
Oncology
Abdul R. Jazieh, Assia A. Bensalem, Adda Bounedjar, Zineb Benbrahim, Mohamed O. Alorabi, Atlal M. Abusanad, Emad M. Tashkandi, Muath A. M. A. Alnassar, Abdul R. A. D. El Kinge, Sana Al-Sukhun, Abdullah Alsharm, Hassan Errihani, Nafisa A. Abdelhafiez, Mohammad Alkaiyat, Hoda Jradi
Summary: The study revealed that the majority of cancer patients in the Middle East and North Africa were worried about contracting COVID-19 and were adhering to precautions such as avoiding hand-shaking, hugging, and social gatherings. However, there was still a significant portion of patients not strictly following these precautions, leading to a higher likelihood of canceling medical appointments or treatment sessions. Improved adherence to preventive measures and maintaining treatment schedules are crucial for the well-being of cancer patients during the pandemic.
Article
Biotechnology & Applied Microbiology
Brice Leyrat, Xavier Durando, Hugo Veyssiere, Maureen Bernadach
Summary: This case involves a 76-year-old Caucasian male with a history of various medical conditions, including lung adenocarcinoma with an intron 14 mutation in the MET gene. The patient showed a durable response to treatment with crizotinib, indicating sensitivity to anti-MET tyrosine kinase inhibitors.
ONCOTARGETS AND THERAPY
(2021)
Article
Oncology
Tressie Herrmann, Angeline Ginzac, Ioana Molnar, Sebastien Bailly, Xavier Durando, Hakim Mahammedi
Summary: In patients with metastatic RCC, eosinophil levels and relative eosinophil change at 6 weeks of nivolumab treatment may serve as good prognostic markers for treatment response, associated with better progression-free survival and overall survival.
Article
Oncology
Hugo Veyssiere, Sejdi Lusho, Ioana Molnar, Myriam Kossai, Maureen Bernadach, Catherine Abrial, Yannick Bidet, Nina Radosevic-Robin, Xavier Durando
Summary: TNBC lacks specific therapy and has poor prognosis. Finding predictive biomarkers for relapse is crucial for management. This study aims to discover such biomarkers, particularly focusing on plasma proteins.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sejdi Lusho, Xavier Durando, Marie-Ange Mouret-Reynier, Myriam Kossai, Nathalie Lacrampe, Ioana Molnar, Frederique Penault-Llorca, Nina Radosevic-Robin, Catherine Abrial
Summary: In this study, baseline TILs remained predictive of pCR, while PLR was a better predictor of positive outcomes in terms of reduced distant recurrences or longer DRFS. Further investigation of baseline PLR alongside TILs may help identify TNBC patients likely to respond well to NACT when TILs are not available.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Nathan El-ghazzi, Xavier Durando, Alexia Giro, Tressie Herrmann
Summary: Endometrial cancer is a rare but aggressive cancer with a low survival rate. Recent advancements in molecular classification have allowed for more targeted treatment options. Immune checkpoint inhibitors such as pembrolizumab have shown promising results in the second-line treatment of advanced EC. There are ongoing investigations into new combinations of pembrolizumab with other drugs that may further improve treatment outcomes.
ONCOTARGETS AND THERAPY
(2023)
Article
Oncology
Angeline Ginzac, Marie-Celeste Ferreira, Anne Cayre, Clement Bouvet, Julian Biau, Ioana Molnar, Nicolas Saroul, Nathalie Pham-Dang, Xavier Durando, Maureen Bernadach
Summary: The NeckTAR trial aims to assess the ability of circulating DNA to predict residual disease in patients with locally advanced head and neck cancer after treatment. A blood sample will be collected before and after radiotherapy, and patients will be followed up for a long period of time. The study could lead to better identification of patients who do not have residual lymph node disease, avoiding unnecessary neck dissection and preserving their quality of life.
Article
Oncology
Hala Mahdi, Layth Mula-Hussain, Zhian S. Ramzi, Marwan Tolba, Omar Abdel-Rahman, Ibrahim Abu-Gheida, Ola Khorshid, Sana Al Sukhun, Nadeem P. Siddiqi, Zahid Al Mandhari, Maysa Al Hussaini
Summary: This study presents the statistics of female cancers in the Arab world in 2020, comparing them with the 2018 statistics and the male and female cancer statistics worldwide. The analysis reveals a relatively high mortality-to-incidence ratio for female cancers in the Arab world compared to worldwide, a lower ratio compared to males, and a consistent ratio with the 2018 data. Further studies are needed to determine the underlying causes of these differences and to develop effective interventions.
JCO GLOBAL ONCOLOGY
(2022)
Article
Oncology
Brice Leyrat, Maureen Bernadach, Angeline Ginzac, Sejdi Lusho, Xavier Durando
Summary: Umbilical skin metastases, also known as Sister Mary Joseph nodules, are rare and typically indicate late-stage deep-seated abdominopelvic malignancies. They are most commonly associated with adenocarcinoma, with an average survival of approximately 11 months. Treatment is challenging and prognosis is poor.
CASE REPORTS IN ONCOLOGY
(2021)
Article
Oncology
Abdul Rahman Jazieh, Anelisa K. Coutinho, Assia A. Bensalem, Abdullah A. Alsharm, Hassan Errihani, Layth Mula-Hussain, Sana Al-Sukhun, Carlos A. Sampaio-Filho, Ola M. R. Khorshid, Roselle B. De Guzman, Mohammad O. Alkaiyat, Hoda A. Jradi
Summary: The study found that the majority of oncologists have good knowledge about preventing and transmitting the virus, yet still worry about getting infected and spreading it to their families. The pandemic has negatively impacted their work and personal lives, including emotional well-being, relationships, research productivity, and financial income.
JCO GLOBAL ONCOLOGY
(2021)